Items Tagged ‘estrogen receptor antagonist’

March 9, 2015

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer


Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST study.1 Both overall survival and time to cancer progression were significantly better with Faslodex® than with the current standard of care, Arimidex®. Each year roughly 200,000 U.S. […]

View full entry

Tags: advanced hormone receptor-positive, anastrozole, Arimidex, Breast Cancer, CONFIRM, estrogen receptor antagonist, Faslodex, fulvestrant, Metastatic Breast Cancer, News, Recurrent Breast Cancer